YIH
CGEM icon

Y-Intercept (HK)’s Cullinan Oncology CGEM Stock Holding History

Y-Intercept (HK)’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.47M Sell
80,648
-14,769
-15% -$219K 0.03% 867
2026
Q1 		$1.36M Buy
+95,417
New +$1.23M 0.03% 906
2025
Q3 		– Sell
-11,129
Closed -$83.8K – 1610
2025
Q2 		$83.8K Buy
+11,129
New +$89.4K ﹤0.01% 1545
2024
Q4 		– Sell
-25,369
Closed -$425K – 1244
2024
Q3 		$425K Buy
25,369
+7,343
+41% +$130K 0.03% 851
2024
Q2 		$314K Buy
+18,026
New +$384K 0.02% 1022

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Y-Intercept (HK)'s CGEM Position: Q2 2026 in Review

Y-Intercept (HK) reduced its Cullinan Oncology (CGEM) stake by 15% in Q2 2026, selling an estimated $219K and leaving 80,648 shares worth $1.47M. The position accounts for 0.03% of the portfolio, ranked #867.

Y-Intercept (HK) first reported a position in CGEM in Q2 2024 and has held it in 5 quarters since. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Y-Intercept (HK) held 80,648 shares of Cullinan Oncology worth $1.47M as of Q2 2026.
  • Y-Intercept (HK) sold 14,769 Cullinan Oncology shares in Q2 2026, an estimated $219K.
  • Cullinan Oncology made up 0.03% of Y-Intercept (HK)'s portfolio in Q2 2026, its #867 holding.
  • Y-Intercept (HK) first reported a position in Cullinan Oncology in Q2 2024 and has held it in 5 quarters since.
  • 184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.